Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1553520

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553520

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug (Targeted Therapy, Immunotherapy, Chemotherapy), By Type, By Distribution Channel, By Region And Segment Forecasts 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is expected to reach USD 9.81 billion by 2030, registering a CAGR of 17.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The targeted therapy segment held the largest market revenue share of 53.0% in 2023 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 36.6% revenue share in 2023. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.5% in 2023.
  • North America liver cancer drug market held a revenue share of 42.7% in 2023.
Show more
Product Code: GVR-2-68038-513-7

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Liver Cancer Drug Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Liver Cancer Drug Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Drug Market: Drug Movement Analysis, 2018 - 2030 (USD Million)
  • 4.3. Targeted Therapy
    • 4.3.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1. Bevacizumab
        • 4.3.1.1.1. Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. Cabozantinib
        • 4.3.1.2.1. Cabozantinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Lenvatinib
        • 4.3.1.3.1. Lenvatinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Ramucirumab
        • 4.3.1.4.1. Ramucirumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.5. Regorafenib
        • 4.3.1.5.1. Regorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.6. Sorafenib
        • 4.3.1.6.1. Sorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.7. Other Targeted Therapies
        • 4.3.1.7.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1. Atezolizumab with Bevacizumab
        • 4.4.1.1.1. Atezolizumab with Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2. Nivolumab with Ipilimumab
        • 4.4.1.2.1. Nivolumab with Ipilimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3. Pembrolizumab
        • 4.4.1.3.1. Pembrolizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.4. Durvalumab with Tremelimumab
        • 4.4.1.4.1. Durvalumab with Tremelimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.5. Other Immunotherapies
        • 4.4.1.5.1. Other Immunotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.1. Gemcitabine
        • 4.5.1.1.1. Gemcitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.2. Oxaliplatin
        • 4.5.1.2.1. Oxaliplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.3. Cisplatin
        • 4.5.1.3.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.4. Doxorubicin
        • 4.5.1.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.5. 5-fluorouracil
        • 4.5.1.5.1. 5-fluorouracil Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.6. Capecitabine
        • 4.5.1.6.1. Capecitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.7. Mitoxantrone
        • 4.5.1.7.1. Mitoxantrone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.8. Other Chemotherapies
        • 4.5.1.8.1. Other Chemotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liver Cancer Drug Market: Type Movement Analysis, 2018 & 2030 (USD Million)
  • 5.3. Hepatocellular Carcinoma
    • 5.3.1. Hepatocellular Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cholangio Carcinoma
    • 5.4.1. Cholangio Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Hepatoblastoma
    • 5.5.1. Hepatoblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Liver Cancer Drug Market: Distribution Channel Movement Analysis, 2018 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

  • 7.1. Liver Cancer Drug Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK.
      • 7.3.2.1. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck KGaA
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Exelixis, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eisai Co., Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bristol-Myers Squibb Company.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bayer AG
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. F. Hoffmann-La Roche Ltd
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!